Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. (2022)

First Author: Harrison CN
Attributed to:  The Oxford Single Cell Biology Consortium funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.2217/fon-2022-0484

PubMed Identifier: 35950489

Publication URI: http://europepmc.org/abstract/MED/35950489

Type: Journal Article/Review

Volume: 18

Parent Publication: Future oncology (London, England)

Issue: 27

ISSN: 1479-6694